Recruiting PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT05937191

Leflunomide for Idiopathic Pulmonary Hemosiderosis in Children (Lef for IPH)

Leflunomide is Safe and Effective for the Induction and Maintenance of Idiopathic Pulmonary Hemosiderosis Remission

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Conditions Idiopathic Pulmonary Hemosiderosis Leflunomide

Updated 3 times since 2023 Last updated: Jun 30, 2023 Started: Jun 1, 2023 Primary completion: Dec 31, 2026 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05937191, this PHASE1/PHASE2 trial focuses on Idiopathic Pulmonary Hemosiderosis and Leflunomide and remains actively recruiting participants. Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, it has been updated 3 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Aug 2023 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Jun 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Data source: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China